• Autophagic Degradation of GluN2B NMDA Receptor Variants in D

  2026-06-02

  Benske et al. reveal that a disease-linked GluN2B R519Q variant is selectively degraded via autophagy rather than trafficked to the neuronal surface. Their mechanistic insights clarify how the autophagy-lysosomal pathway and ER-phagy receptors govern the fate of misfolded NMDA receptor subunits, informing strategies for targeted intervention in GRIN-related neurological disorders.

• IR-820 (New Indocyanine Green): Advanced In Vivo Imaging Pro

  2026-06-02

  IR-820 (New Indocyanine Green) delivers ultrasensitive near-infrared fluorescence for precise vascular and tumor quantification in living models. This guide details experimental workflows, troubleshooting insights, and the latest nanoplatform advances that maximize the research impact of IR-820. Discover how APExBIO's reagent enables next-generation in vivo imaging and synergistic cancer therapy studies.

• Smoothened Agonist (SAG): Driving Precision Hedgehog Activat

  2026-06-01

  Smoothened Agonist (SAG) empowers researchers with reproducible Hedgehog pathway activation for myelin regeneration, stem cell maintenance, and disease modeling. Its selective action, robust solubility, and nuanced immune effects make it the preferred tool for advanced neurobiology and developmental studies.

• Optimizing Translational Protein Analysis: Power of RIPA Lys

  2026-06-01

  This article delivers advanced mechanistic and strategic guidance for translational researchers on maximizing protein extraction and assay fidelity using RIPA Lysis Buffer (Strong, without inhibitors). By connecting the buffer’s robust detergent action with its flexibility for custom inhibitor addition, the discussion bridges experimental rigor with evolving needs in metabolic research—exemplified by recent breakthroughs in brown adipose tissue thermogenesis and obesity intervention.

• CKI 7 Dihydrochloride: Precision Tools for CK1 Pathway Disse

  2026-05-31

  Explore how CKI 7 dihydrochloride enables innovative Casein kinase 1 inhibitor assays, offering a unique perspective on CK1’s role in metastasis, signaling, and circadian regulation. Uncover actionable insights for advanced cancer and cell biology research.

• Berbamine hydrochloride: Reliable Solutions for Cancer Resea

  2026-05-30

  Explore how Berbamine hydrochloride (SKU N2471) addresses common laboratory challenges in cancer research, including assay reproducibility, pathway-specific cytotoxicity, and workflow integration. This scenario-driven article delivers validated guidance for biomedical researchers and lab technicians using Berbamine hydrochloride.

• EdU Imaging Kits (Cy5): Advancing S-Phase Analysis in Transl

  2026-05-29

  This thought-leadership article explores the mechanistic and translational significance of EdU Imaging Kits (Cy5) for precise S-phase DNA synthesis measurement. Integrating evidence from recent ovarian granulosa cell research and advances in click chemistry, it offers strategic guidance for researchers aiming to bridge cell proliferation assays with clinical and pharmacodynamic applications. The discussion addresses technical validation, competitive benchmarks, and future directions for high-impact research.

• Unlocking NAMPT Inhibition: FK866 (APO866) in Translational

  2026-05-29

  This thought-leadership article explores the mechanistic foundation and translational impact of FK866 (APO866), a potent NAMPT inhibitor, in hematologic cancer research. By bridging emerging immunometabolic insights with practical experimental protocols and strategic perspectives, it equips researchers to leverage FK866 as both a benchmark tool and a springboard for next-generation host-directed therapies.

• Dye Models for Small Biopsy Visibility in Surgical Pathology

  2026-05-28

  This study systematically evaluated dye models for enhancing the visibility of small tissue biopsies during pathology workflows, identifying hematoxylin as the optimal marking agent due to its low toxicity and non-interference with diagnostic procedures. The findings inform improved pre-analytical protocols and highlight considerations for dye selection in histological assays.

• Flavopiridol (A3417): Reliable Pan-CDK Inhibition for Cell A

  2026-05-28

  This article offers evidence-driven guidance for leveraging Flavopiridol (SKU A3417) as a pan-CDK inhibitor in cell viability, proliferation, and cytotoxicity workflows. By addressing real laboratory challenges—ranging from protocol optimization to vendor reliability—it illustrates how Flavopiridol (A3417) ensures reproducibility and data integrity for cancer research and cell cycle arrest studies.

• Annexin V-FITC/7-AAD Apoptosis Kit: Technical Workflow Guide

  2026-05-27

  The Annexin V-FITC/7-AAD Apoptosis Kit offers a streamlined, reliable method for distinguishing apoptotic from necrotic cells in cell viability and cytotoxicity assays. It is best utilized in established phosphatidylserine binding workflows with flow cytometry or fluorescence microscopy. This kit is not intended for mechanistic studies of cell death pathways or for use with atypical cell types outside standard apoptosis and necrosis detection.

• HyperFluor™ 594 Goat Anti-Rabbit IgG: Precision in Immunodet

  2026-05-27

  HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody enables high-sensitivity, multiplexed detection of rabbit IgG in immunocytochemistry, immunohistochemistry, and flow cytometry workflows. By combining robust specificity with a bright, stable fluorophore, this APExBIO secondary antibody streamlines translational research targeting disease biomarkers such as ISG20 and CLEC5A.

• ICG001: Unlocking EMT and Fibrosis Mechanisms for Translatio

  2026-05-26

  ICG001, a potent Wnt/β-catenin pathway inhibitor from APExBIO, is reshaping translational research in fibrosis and cancer. By targeting the CBP/β-catenin interaction, ICG001 enables high-resolution dissection of epithelial–mesenchymal transition (EMT) and downstream fibrotic processes. This article bridges recent breakthroughs in MMP7-driven liver fibrosis with actionable guidance for experimental design, protocol optimization, and strategic differentiation in translational pipelines. Grounded in mechanistic rigor and backed by emerging literature, we outline how ICG001 empowers researchers to address unmet needs in disease modeling and therapeutic innovation.

• Deferasirox: Redefining Iron Chelation in Cancer Translation

  2026-05-26

  This thought-leadership article explores Deferasirox’s multifaceted role as an oral iron chelator at the intersection of iron overload therapy and advanced cancer research. We dissect its mechanistic impact on tumor biology, contextualize recent findings on ferroptosis resistance in hepatocellular carcinoma, and deliver actionable guidance for translational researchers pursuing iron metabolism as a therapeutic lever. The discussion integrates evidence from cutting-edge studies and workflow best practices, while highlighting how Deferasirox from APExBIO offers a uniquely powerful and reliable tool for probing iron-dependent pathways.

• (1S,3R)-RSL3: Expanding GPX4 Inhibition Beyond Cancer Models

  2026-05-25

  Explore the versatile role of (1S,3R)-RSL3 glutathione peroxidase 4 inhibitor in ferroptosis research. This article uniquely examines RSL3's applications beyond cancer, delving into aging, oxidative stress, and lens biology.

451 records 16/31 page Previous Next First page 上5页 1617181920 下5页 Last page